XML 68 R23.htm IDEA: XBRL DOCUMENT

Collaboration Agreements (Tables)

9 Months Ended

Sep. 27, 2019

Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Takeda collaboration revenues	$	1,187	$	1,940	$	14,245	$	6,843

Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Ipsen collaboration revenues	$	76,016	$	57,186	$	120,133	$	145,038

Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Profits on U.S. commercialization	$	1,102	$	1,935	$	3,507	$	6,004
Royalty revenues on ex-U.S. sales	$	1,614	$	1,390	$	4,426	$	4,285

Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):



	Nine Months Ended September 30,
	2019		2018
Daiichi Sankyo collaboration revenues	$	20,130	$	20,000

Such royalties accruing to GSK were as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Royalties accruing to GSK	$	7,964	$	6,268	$	23,079	$	17,021